Overexpression of long non‑coding RNA colon cancer‑associated transcript 2 is associated with advanced tumor progression and poor prognosis in patients with colorectal cancer

Zhang,Junling; Jiang,Yong; Zhu,Jing; Wu,Tao; Ma,Ju; Du,Chuang; Chen,Shanwen; Li,Tengyu; Han,Jinsheng; Wang,Xin

doi:10.3892/ol.2017.7049

Overexpression of long non‑coding RNA colon cancer‑associated transcript 2 is associated with advanced tumor progression and poor prognosis in patients with colorectal cancer

Authors:
- Junling Zhang
- Yong Jiang
- Jing Zhu
- Tao Wu
- Ju Ma
- Chuang Du
- Shanwen Chen
- Tengyu Li
- Jinsheng Han
- Xin Wang
View Affiliations

Affiliations: Department of General Surgery, Peking University First Hospital, Peking University, Beijing 100034, P.R. China, Department of General Surgery, The People's Hospital of Hebei, Shijiazhuang, Hebei 050000, P.R. China
Published online on: September 25, 2017 https://doi.org/10.3892/ol.2017.7049
Pages: 6907-6914

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to explore the clinicopathological and prognostic significance of long non‑coding RNA (lncRNA) colon cancer‑associated transcript 2 (CCAT2) expression in human colorectal cancer (CRC). Expression levels of lncRNA CCAT2 in CRC, adjacent non‑tumor and healthy colon mucosa tissues were detected by quantitative polymerase chain reaction. The disease‑free survival and overall survival rates were evaluated using the Kaplan‑Meier method, and multivariate analysis was performed using Cox proportional hazard analysis. The expression level of lncRNA CCAT2 in CRC tissues was increased significantly compared with adjacent normal tissues or non‑cancerous tissues. CCAT2 expression was observed to be progressively increased between tumor‑node‑metastasis (TNM) stages I and IV. A high level of CCAT2 expression was revealed to be associated with poor cell differentiation, deeper tumor infiltration, lymph node metastasis, distance metastasis, vascular invasion and advanced TNM stage. Compared with patients with low levels of CCAT2 expression, patients with high levels of CCAT2 expression had shorter disease‑free survival and overall survival times. Multivariate analyses indicated that high CCAT2 expression was an independent poor prognostic factor. Therefore, increased lncRNA CCAT2 expression maybe a potential diagnostic biomarker for CRC, and an independent predictor of prognosis in patients with CRC.

View Figures

View References

1	Brenner H, Kloor M and Pox CP: Colorectal cancer. Lancet. 383:1490–1502. 2014. View Article : Google Scholar : PubMed/NCBI
2	Fedirko V, Romieu I, Aleksandrova K, Pischon T, Trichopoulos D, Peeters PH, Romaguera-Bosch D, Bueno-de-Mesquita HB, Dahm CC, Overvad K, et al: Pre-diagnostic anthropometry and survival after colorectal cancer diagnosis in Western European populations. Int J Cancer. 135:1949–1960. 2014. View Article : Google Scholar : PubMed/NCBI
3	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
4	Gustavsson B, Carlsson G, Machover D, Petrelli N, Roth A, Schmoll HJ, Tveit KM and Gibson F: A review of the evolution of systemic chemotherapy in the management of colorectal cancer. Clin Colorectal Cancer. 14:1–10. 2015. View Article : Google Scholar : PubMed/NCBI
5	Teufel A, Gerken M, Hartl J, Itzel T, Fichtner-Feigl S, Stroszczynski C, Schlitt HJ, Hofstädter F and Klinkhammer-Schalke M: Benefit of adjuvant chemotherapy in patients with T4 UICC II colon cancer. BMC Cancer. 15:4192015. View Article : Google Scholar : PubMed/NCBI
6	Barton MK: Oxaliplatin in the adjuvant treatment of colon cancer. CA Cancer J Clin. 62:3–4. 2012. View Article : Google Scholar : PubMed/NCBI
7	Wolpin BM, Meyerhardt JA, Mamon HJ and Mayer RJ: Adjuvant treatment of colorectal cancer. CA Cancer J Clin. 57:168–185. 2007. View Article : Google Scholar : PubMed/NCBI
8	Angrand PO, Vennin C, Le Bourhis X and Adriaenssens E: The role of long non-coding RNAs in genome formatting and expression. Front Genet. 6:1652015. View Article : Google Scholar : PubMed/NCBI
9	Esteller M: Non-coding RNAs in human disease. Nat Rev Genet. 12:861–874. 2011. View Article : Google Scholar : PubMed/NCBI
10	Xie X, Tang B, Xiao YF, Xie R, Li BS, Dong H, Zhou JY and Yang SM: Long non-coding RNAs in colorectal cancer. Oncotarget. 7:5226–5239. 2016. View Article : Google Scholar : PubMed/NCBI
11	Deng Q, He B, Gao T, Pan Y, Sun H, Xu Y, Li R, Ying H, Wang F, Liu X, et al: Up-regulation of 91H promotes tumor metastasis and predicts poor prognosis for patients with colorectal cancer. PLoS One. 9:e1030222014. View Article : Google Scholar : PubMed/NCBI
12	Yu H, Xu Q, Liu F, Ye X, Wang J and Meng X: Identification and validation of long noncoding RNA biomarkers in human non-small-cell lung carcinomas. J Thorac Oncol. 10:645–654. 2015. View Article : Google Scholar : PubMed/NCBI
13	Svoboda M, Slyskova J, Schneiderova M, Makovicky P, Bielik L, Levy M, Lipska L, Hemmelova B, Kala Z, Protivankova M, et al: HOTAIR long non-coding RNA is a negative prognostic factor not only in primary tumors, but also in the blood of colorectal cancer patients. Carcinogenesis. 35:1510–1515. 2014. View Article : Google Scholar : PubMed/NCBI
14	Zheng HT, Shi DB, Wang YW, Li XX, Xu Y, Tripathi P, Gu WL, Cai GX and Cai SJ: High expression of lncRNA MALAT1 suggests a biomarker of poor prognosis in colorectal cancer. Int J Clin Exp Pathol. 7:3174–3181. 2014.PubMed/NCBI
15	Ling H, Spizzo R, Atlasi Y, Nicoloso M, Shimizu M, Redis RS, Nishida N, Gafà R, Song J, Guo Z, et al: CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res. 23:1446–1461. 2013. View Article : Google Scholar : PubMed/NCBI
16	Edge SB and Compton CC: The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Zheng R, Zeng H, Zhang S, Chen T and Chen W: National estimates of cancer prevalence in China, 2011. Cancer Lett. 13:00620–00625. 2015.
19	Brenner H, Kloor M and Pox CP: Colorectal cancer. Lancet. 383:1490–1502. 2014. View Article : Google Scholar : PubMed/NCBI
20	Li W, Qiu T, Ling Y, Guo L, Li L and Ying J: Molecular pathological epidemiology of colorectal cancer in Chinese patients with KRAS and BRAF mutations. Oncotarget. 6:39607–39613. 2015. View Article : Google Scholar : PubMed/NCBI
21	Carethers JM: Biomarker-directed Targeted therapy in colorectal cancer. J Dig Cancer Rep. 3:5–10. 2015.PubMed/NCBI
22	Tsikitis VL, Larson DW, Huebner M, Lohse CM and Thompson PA: Predictors of recurrence free survival for patients with stage II and III colon cancer. BMC cancer. 14:3362014. View Article : Google Scholar : PubMed/NCBI
23	Rodriguez-Moranta F, Saló J, Arcusa A, Boadas J, Piñol V, Bessa X, Batiste-Alentorn E, Lacy AM, Delgado S, Maurel J, et al: Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: A prospective, multicenter, randomized, controlled trial. J Clin Oncol. 24:386–393. 2006. View Article : Google Scholar : PubMed/NCBI
24	Schmoll HJ, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, Hill M, Hoersch S, Rittweger K and Haller DG: Capecitabine plus oxaliplatin compared with fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: Final results of the NO16968 randomized controlled phase III trial. J Clin Oncol. 33:3733–3740. 2015. View Article : Google Scholar : PubMed/NCBI
25	Schmitt AM and Chang HY: Long Noncoding RNAs in Cancer Pathways. Cancer Cell. 29:452–463. 2016. View Article : Google Scholar : PubMed/NCBI
26	Meseure D, Drak Alsibai K, Nicolas A, Bieche I and Morillon A: Long noncoding RNAs as new Architects in cancer epigenetics, prognostic biomarkers, and potential therapeutic targets. Biomed Res Int. 2015:3202142015. View Article : Google Scholar : PubMed/NCBI
27	Kugimiya N, Nishimoto A, Hosoyama T, Ueno K, Enoki T, Li TS and Hamano K: The c-MYC-ABCB5 axis plays a pivotal role in 5-fluorouracil resistance in human colon cancer cells. J Cell Mol Med. 19:1569–1581. 2015. View Article : Google Scholar : PubMed/NCBI